TECVAYLI 90 mg/mL solution for injection clinical trials

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy

This study is looking at a medicine called Gammagard Liquid, which helps protect against infections in adults with a type of blood cancer called multiple myeloma. These patients are also receiving another new treatment. Researchers want to see if Gammagard Liquid is better at preventing serious infections from happening in the first place.